<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
Certification and Notice of Termination of Registration under Section 12(g)
of the Securities Exchange Act of 1934 or Suspension of Duty to File Reports
Under Sections 13 and 15(d) of the Securities Exchange Act of 1934
Commission File Number: 0-19910
CREATIVE BIOMOLECULES, INC.
--------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
45 South Street, Hopkinton, Massachusetts 01748 (508) 782-1100
--------------------------------------------------------------------------------
(Address, including Zip Code, and Telephone Number, including Area Code, of
Registrant's Principal Executive Offices)
Common Stock, par value $.01 per share
--------------------------------------------------------------------------------
(Title of Each Class of Securities Covered by this Form)
None
--------------------------------------------------------------------------------
(Titles of All Other Classes of Securities For Which a Duty to Filed Reports
Under Section 13(a) or 15(d) Remains)
Please place an X in the box(es) to designate to appropriate rule
provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1)(i) [X]/*/ Rule 12h-3(b)(1)(i) [X]
Rule 12g-4(a)(1)(ii) [_] Rule 12h-3(b)(2)(i) [_]
Rule 12g-4(a)(2)(i) [_] Rule 12h-3(b)(2)(ii) [_]
Rule 12g-4(a)(2)(ii) [_] Rule 15d-6 [_]
Rule 12h-3(b)(1)(i) [_]
Approximate number of holders of record as of the certification or notice
date: 0
Common Stock, par value $.01 per share:
Pursuant to the requirements of the Securities Exchange Act of 1934,
has caused this certification/notice to be signed on its behalf by the
undersigned duly authorized person.
--------------------------------------------------------------------------------
/*/ On July 31, 2000, Creative BioMolecules, Inc. was merged with and into
Curis, Inc. upon the consummation of a certain merger agreement among
Curis, Inc., Creative BioMolecules, Inc., Ontogeny, Inc. and
Reprogenesis, Inc. Accordingly, and pursuant to the requirements of the
Securities Exchange Act of 1934, as amended, and Rule 12g-4 thereunder,
Curis, Inc., as successor issuer, has caused this Certification to be
executed and filed by the undersigned duly authorized person on behalf of
Creative Biomolecules, Inc.
CURIS, INC.
Date: July 31, 2000 By: /s/ Doros Platika
------------------------------
Doros Platika, President and
Chief Executive Officer
